Newsroom | 32292 results

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 164,500 shares of common stock to nine new employees under the Company’s 2024 Induceme...

WASHINGTON--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, is deeply alarmed by the Trump Administration’s budget proposal for fiscal year 2026 (FY26) which would eliminate all funding for critical cancer prevention and control programs, including the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), and significantly cut life-saving research at the Department of Health and Human Services (HHS), including the National Institutes of Health...

LOS ANGELES--(BUSINESS WIRE)--The official trailer for “Shelter Me: The Cancer Pioneers” has just dropped, giving audiences a moving first look at the groundbreaking new documentary that follows the emotional and inspiring journey of dogs helping to pioneer cancer treatments that are saving human lives. The movie will stream through the PBS app and on PBS.org starting on Thursday, May 15. The newest film in the Emmy Award-winning “Shelter Me” series, ‘The Cancer Pioneers’ brings viewers inside...

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced an intended expansion of its radiation oncology portfolio as well as the introduction of the new AI-enabled MR Contour DL™ at the European Society for Therapeutic Radiology and Oncology (ESTRO) 2025 Congress in Vienna, Austria. The company will also showcase its updated Intelligent Radiation Therapy (iRT), a software solution that standardizes complex workflows, helping to enable a shorter timeline from diagnosis to treatmen...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted three newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on May 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on...

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly” or the “Company”), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, “2025 is off to a great start. The Butterfly team hit the mark...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.co...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its new generation pan-TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), which accepted the New Drug Application (NDA) of zurletrectinib for the treatment of patients with advanced solid tumors harboring NTRK...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab, a bispecific antibody being investigated in combination with rituximab and lenalidomide (R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), following at least one prior systemic therapy. The...

サンディエゴ--(BUSINESS WIRE)--（ビジネスワイヤ） -- 米国に本社を置き、JSRライフサイエンスおよび日本に本社を置くJSR株式会社傘下のグローバルCRO（開発業務受託機関）であるCrown Bioscienceは、世界最大級のフェーズIオンコロジー臨床試験ネットワークの一つであるNEXT Oncologyとの提携を延長することを発表いたします。この戦略的提携により、Crown Bioscienceの臨床的に意義のあるがんオルガノイドおよび患者由来異種移植（PDX）モデルの開発における豊富な経験と、NEXT Oncologyのグローバルな臨床ネットワークおよびフェーズI臨床試験の専門知識を、引き続き活用していくことになります。 この契約延長により、Crown Bioscienceは、NEXT Oncologyの業界をリードするグローバル臨床試験ネットワークから提供される患者サンプルに基づくサービスを提供する独占的権利を再確認します。この提携は、トランスレーショナル・オンコロジー研究において、臨床的に最も関連性の高いPDXおよびオルガノイドモデルとソリューションを提...